The differences in plasma LD concentrations between men and women over time.
Original research article Front. Med., 31 May 2022
frontiersin.org/articles/10...
On my search for the Pharmacokinetics, pharmacodynamics of the various C/L medications, I came across this remarkable research from last year. Maybe someone else has already posted this, in which case I apologise. For me it was new and the results reaffirmed my suspicion that after all these years the PD medication is still often based on standard procedures and is hardly tailored to the individual according to the latest (and even older) scientific insights. Because you apparently have to do that yourself, collecting this type of information is crucial to understanding and handling your possible over- and under-dosing. 🍀
Results
The LD concentrations were measured in plasma from 35 Caucasian patients (19 men and 16 women) with PD. All of them were LD-naïve patients and received a single dose of oral LD/benserazide (100/25 mg) formulation.
The study population appeared to be homogenous for the age and duration of the disease. No differences were found in BMI median value between men and women, while women had a median value of BW lower than men. Daily energy consumption and lean mass were higher in men than in women, while women showed higher fat mass compared with men without reaching a statistical significance. There was no difference in PD symptoms, monoamine oxidase-B inhibitors (iMAO-B), dopamine agonists (DA) use, and comorbidities between genders. The main characteristics of the study population are listed in Table 1. No differences were found in dietary habits (data not shown).
Conclusion
Taken together, our findings provide novel insights into gender differences in LD pharmacokinetics, possibly contributing to the later development of motor complications and dyskinesia in PD. The results refer to parameters measured at the first drug intake of patients enrolled in an ongoing study with a 2-year follow-up. Future analyses will allow us to assess whether the highlighted differences translate into different patterns of adverse events in men and women.